Promotion deal is huge boost for Exact – but Pfizer must deliver
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Merck & Co hedges its checkpoint bet with Lenvima
Eisai deal to help Merck expand checkpoint inhibitor franchise.
Takeda forges another neuroscience deal as Abbvie dips a toe
Takeda's appetite for risk in early stage neuroscience could make it one to watch.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.